TY - JOUR
T1 - Prediagnostic serum glyceraldehyde-derived advanced glycation end products and mortality among colorectal cancer patients
AU - Mao, Ziling
AU - Baker, Jacqueline Roshelli
AU - Takeuchi, Masayoshi
AU - Hyogo, Hideyuki
AU - Tjønneland, Anne
AU - Eriksen, Anne Kirstine
AU - Severi, Gianluca
AU - Rothwell, Joseph
AU - Laouali, Nasser
AU - Katzke, Verena
AU - Kaaks, Rudolf
AU - Schulze, Matthias B.
AU - Palli, Domenico
AU - Sieri, Sabina
AU - de Magistris, Maria Santucci
AU - Tumino, Rosario
AU - Sacerdote, Carlotta
AU - Derksen, Jeroen W.G.
AU - Gram, Inger T.
AU - Skeie, Guri
AU - Sandanger, Torkjel M.
AU - Quirós, Jose Ramón
AU - Crous-Bou, Marta
AU - Sánchez, Maria Jose
AU - Amiano, Pilar
AU - Colorado-Yohar, Sandra M.
AU - Guevara, Marcela
AU - Harlid, Sophia
AU - Johansson, Ingegerd
AU - Perez-Cornago, Aurora
AU - Freisling, Heinz
AU - Gunter, Marc
AU - Weiderpass, Elisabete
AU - Heath, Alicia K.
AU - Aglago, Elom
AU - Jenab, Mazda
AU - Fedirko, Veronika
N1 - Publisher Copyright:
© 2023 UICC.
PY - 2023/6/1
Y1 - 2023/6/1
N2 - Glyceraldehyde-derived advanced glycation end products (glycer-AGEs) could contribute to colorectal cancer development and progression due to their pro-oxidative and pro-inflammatory properties. However, the association of glycer-AGEs with mortality after colorectal cancer diagnosis has not been previously investigated. Circulating glycer-AGEs were measured by competitive ELISA. Multivariable Cox proportional hazards models were used to calculate hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) for associations of circulating glycer-AGEs concentrations with CRC-specific and all-cause mortality among 1034 colorectal cancer (CRC) cases identified within the European Prospective Investigation into Cancer and Nutrition (EPIC) study between 1993 and 2013. During a mean of 48 months of follow-up, 529 participants died (409 from CRC). Glycer-AGEs were statistically significantly positively associated with CRC-specific (HRQ5 vs Q1 = 1.53, 95% CI: 1.04-2.25, Ptrend =.002) and all-cause (HRQ5 vs Q1 = 1.62, 95% CI: 1.16-2.26, Ptrend <.001) mortality among individuals with CRC. There was suggestion of a stronger association between glycer-AGEs and CRC-specific mortality among patients with distal colon cancer (per SD increment: HRproximal colon = 1.02, 95% CI: 0.74-1.42; HRdistal colon = 1.51, 95% CI: 1.20-1.91; Peffect modification =.02). The highest HR was observed among CRC cases in the highest body mass index (BMI) and glycer-AGEs category relative to lowest BMI and glycer-AGEs category for both CRC-specific (HR = 1.78, 95% CI: 1.02-3.01) and all-cause mortality (HR = 2.15, 95% CI: 1.33-3.47), although no statistically significant effect modification was observed. Our study found that prediagnostic circulating glycer-AGEs are positively associated with CRC-specific and all-cause mortality among individuals with CRC. Further investigations in other populations and stratifying by tumor location and BMI are warranted.
AB - Glyceraldehyde-derived advanced glycation end products (glycer-AGEs) could contribute to colorectal cancer development and progression due to their pro-oxidative and pro-inflammatory properties. However, the association of glycer-AGEs with mortality after colorectal cancer diagnosis has not been previously investigated. Circulating glycer-AGEs were measured by competitive ELISA. Multivariable Cox proportional hazards models were used to calculate hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) for associations of circulating glycer-AGEs concentrations with CRC-specific and all-cause mortality among 1034 colorectal cancer (CRC) cases identified within the European Prospective Investigation into Cancer and Nutrition (EPIC) study between 1993 and 2013. During a mean of 48 months of follow-up, 529 participants died (409 from CRC). Glycer-AGEs were statistically significantly positively associated with CRC-specific (HRQ5 vs Q1 = 1.53, 95% CI: 1.04-2.25, Ptrend =.002) and all-cause (HRQ5 vs Q1 = 1.62, 95% CI: 1.16-2.26, Ptrend <.001) mortality among individuals with CRC. There was suggestion of a stronger association between glycer-AGEs and CRC-specific mortality among patients with distal colon cancer (per SD increment: HRproximal colon = 1.02, 95% CI: 0.74-1.42; HRdistal colon = 1.51, 95% CI: 1.20-1.91; Peffect modification =.02). The highest HR was observed among CRC cases in the highest body mass index (BMI) and glycer-AGEs category relative to lowest BMI and glycer-AGEs category for both CRC-specific (HR = 1.78, 95% CI: 1.02-3.01) and all-cause mortality (HR = 2.15, 95% CI: 1.33-3.47), although no statistically significant effect modification was observed. Our study found that prediagnostic circulating glycer-AGEs are positively associated with CRC-specific and all-cause mortality among individuals with CRC. Further investigations in other populations and stratifying by tumor location and BMI are warranted.
KW - advanced glycation end products
KW - colorectal cancer
KW - glyceraldehyde-derived advanced glycation end products
KW - mortality
KW - prospective study
UR - http://www.scopus.com/inward/record.url?scp=85150753434&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85150753434&partnerID=8YFLogxK
U2 - 10.1002/ijc.34449
DO - 10.1002/ijc.34449
M3 - Article
C2 - 36715363
AN - SCOPUS:85150753434
SN - 0020-7136
VL - 152
SP - 2257
EP - 2268
JO - International journal of cancer
JF - International journal of cancer
IS - 11
ER -